| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a National Cancer Institute, Bethesda, Maryland; b Memorial Sloan-Kettering Cancer Center, New York, New York; c Evanston Northwestern Healthcare, Evanston, Illinois; d Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts; e Stanford University Medical Center, Stanford, California; f Ortho Biotech Products, L.P., Raritan, New Jersey; g Vanderbilt University, Nashville, Tennessee; h University of California San Francisco, San Francisco, California; i The National Coalition for Cancer Survivorship, Silver Spring, Maryland; j Beth Israel Medical Center, New York, New York; k The University of Chicago, Chicago, Illinois
Correspondence: Gregory A. Curt, M.D., National Cancer Institute, 12N214 Room Bldg. 10, Bethesda, Maryland 20892-0001, USA; Telephone: 301-496-4251; Fax: 301-496-9962; e-mail: gc45e{at}nih.gov
| ABSTRACT |
|---|
|
|
|---|
Patients and Methods. A 25-minute telephone interview was completed with 379 cancer patients having a prior history of chemotherapy. Patients were recruited from a sample of 6,125 households in the United States identified as having a member with cancer. The median patient age was 62 years, and 79% of respondents were women. Patients reporting fatigue at least a few times a month were asked a series of questions to better describe their fatigue and its impact on quality of life.
Results. Seventy-six percent of patients experienced fatigue at least a few days each month during their most recent chemotherapy; 30% experienced fatigue on a daily basis. Ninety-one percent of those who experienced fatigue reported that it prevented a "normal" life, and 88% indicated that fatigue caused an alteration in their daily routine. Fatigue made it more difficult to participate in social activities and perform typical cognitive tasks. Of the 177 patients who were employed, 75% changed their employment status as a result of fatigue. Furthermore, 65% of patients indicated that their fatigue resulted in their caregivers taking at least one day (mean, 4.5 days) off work in a typical month. Physicians were the health care professionals most commonly consulted (79%) to discuss fatigue. Bed rest/ relaxation was the most common treatment recommendation (37%); 40% of patients were not offered any recommendations.
Conclusions. Cancer-related fatigue is common among cancer patients who have received chemotherapy and results in substantial adverse physical, psychosocial, and economic consequences for both patients and caregivers. Given the impact of fatigue, treatment options should be routinely considered in the care of patients with cancer.
Key Words. Asthenia • Cancer • Chemotherapy • Fatigue • Fatigue Coalition • Quality of life
| INTRODUCTION |
|---|
|
|
|---|
The incidence and severity of cancer-related fatigue appear to be influenced by characteristics of the patient [9, 11-13], primary malignancy, and type/intensity of treatment [2]. Fatigue has been reported in 80% to 99% of cancer patients who undergo treatment with chemotherapy, radiotherapy, or both [5, 12, 14, 15]. Although the relative importance of physical (e.g., anemia, cachexia), psychological (e.g., depression, anxiety), and situational (e.g., sleep deprivation) factors is usually unclear [2, 9, 10, 14, 16, 17], these and other factors appear to be important in the pathogenesis and may be predominant in some cases.
Interest in characterizing the epidemiology and pathogenesis of cancer-related fatigue has intensified in recent years [2]. Research on this subject has been limited, however, and evaluation of data from previous studies is complicated by variations in defining and assessing fatigue and its relatively high prevalence in the general population [10, 17]. Recent acceptance of cancer-related fatigue as a diagnosis in the International Classification of Diseases 10th Revision-Clinical Modification (ICD-10) should help ensure a standardized diagnosis in research settings and clinical practice [2, 3].
The Fatigue Coalition, a multidisciplinary group of medical practitioners/researchers (oncology, HIV/AIDS, palliative care, psychiatry, psychology) and patient advocates, was formed to study the incidence, prevalence, and functional impact of fatigue in patients with cancer and to develop diagnosis and treatment guidelines (Appendix). In 1996, we conducted the first large-scale, population-based survey to characterize the epidemiology of cancer-related fatigue and its impact from the perspectives of patients, primary caregivers, and oncologists [6]. Data from that tripart survey confirmed that fatigue is highly prevalent, causes substantial functional and psychological impairment, and is rarely discussed or treated [6]. In an effort to better understand the nature of cancer-related fatigue in patients receiving chemotherapy, we conducted a second survey specifically designed to A) confirm the conclusions of the first survey concerning the prevalence and relative importance of fatigue as a side effect of cancer treatment; B) clarify the experience of fatigue in patients; C) further explore the impact of fatigue on the daily lives of both patients and caregivers, and D) develop insights into how physicians can better communicate with their cancer patients. Unlike our first survey, the present survey evaluated the duration of fatigue and the economic/occupational impact of fatigue on both patients and caregivers.
| PATIENTS AND METHODS |
|---|
|
|
|---|
Initially, patients were asked background questions about their current condition and medical history (e.g., type of cancer, side effects experienced during and after chemotherapy) and how often they had experienced fatigue (defined as a general feeling of debilitating tiredness or loss of energy). Patients who reported they "hardly ever" experienced fatigue were asked only a few additional demographic questions for statistical purposes. Those who experienced fatigue at least a few days each month were asked a series of questions aimed at describing fatigue, its impact compared with the other common chemotherapy-induced side effects of nausea, pain, and depression, and the level of communication with health care professionals. Additional questions examined the impact of fatigue on daily functioning, including physical, mental/emotional, behavioral/social, and occupational/economic effects. Patients also were asked questions that examined the occupational/economic effects of their fatigue and chemotherapy regimen on primary caregivers. Types of questions addressing the impact of fatigue consisted primarily of open-ended questions and lists of statements, which were read to patients and answered with "yes" or "no" responses.
Descriptive statistics were used to summarize demographic variables. Differences in responses by demographic variables (e.g., gender, age) were tested for significance using two-tailed t-tests. p values <.05 were considered statistically significant.
| RESULTS |
|---|
|
|
|---|
Patient demographics for the 379 patients are shown in Table 1
. The median patient age was 62 years. Fifty-three percent of the interviewed patients received chemotherapy only, whereas the remainder (47%) had a history of chemotherapy and radiotherapy. Forty percent of patients had their last chemotherapy treatment within the past two years, whereas 60% had been treated with chemotherapy more than two years previously.
|
| PREVALENCE AND DURATION OF FATIGUE |
|---|
|
|
|---|
|
|
|
| IMPACT OF FATIGUE |
|---|
|
|
|---|
Of the 301 patients who reported fatigue, 275 (91%) said it prevented them from leading a "normal" life, and 266 (88%) indicated an alteration of their daily routine due to fatigue. Sixty percent of patients who experienced fatigue and pain, nausea, or depression (n = 198) reported that fatigue affected their daily lives the most (Table 4
). Specific daily activities identified as being more difficult when experiencing fatigue included walking distances, general household chores, cleaning/straightening up the house, social activities, and food preparation (Fig. 2
). On average, when feeling fatigued, patients reported an ability to accomplish only 55% of activities normally performed. Subsets of patients more likely to have their daily routine significantly affected by fatigue included those who were aged 55-64 years (60% versus 44% of younger and older patients; p < .05) or active prior to diagnosis (58% versus 39% of those less active; p < .05). Patients who experienced fatigue on a daily basis were significantly more likely to have been experiencing pain (32%) than those who experienced fatigue less frequently (17% of patients who experienced fatigue at least once a week or on most days and 8% of patients who experienced fatigue only a few days per month; p < .05). Patients who experienced fatigue on a daily basis were also significantly more likely to have reported depression (32%) than those experiencing fatigue only for a few days each month (14%; p < .05).
|
|
| PSYCHOSOCIAL |
|---|
|
|
|---|
30% of patients are summarized in Figure 3
54 years) were almost twice as likely as older patients to have felt that people did not understand what their fatigue felt like (60% versus 33% of those older; p < .05), reported feeling depressed or hopeless (51% versus 29% of those older; p < .05), and indicated that they occasionally felt like they wanted to die (28% versus 15% of those aged
65 years; p < .05).
|
30% of patients when experiencing fatigue are summarized in Figure 4
|
| ECONOMIC/OCCUPATIONAL |
|---|
|
|
|---|
|
| PATIENT-PHYSICIAN COMMUNICATION |
|---|
|
|
|---|
| MANAGEMENT OF FATIGUE |
|---|
|
|
|---|
|
| DISCUSSION |
|---|
|
|
|---|
Experience indicates that evaluation of fatigue in cancer patients is difficult due to the subjectivity of this measure of functional performance [22]. Therefore, explicit questions concerning common daily activities were asked in attempts to improve the objectivity of our survey. The reported effects of fatigue on daily physical and psychosocial functioning of cancer patients were substantial and consistent with results of previous studies [4, 7, 8, 15, 23, 24]. Most patients who reported fatigue said it prevented them from leading a normal life and conducting their daily routine. Social activities, such as going to a restaurant and spending time with friends, became more difficult. Fatigue was also associated with a wide range of symptoms consistent with psychological impairment, including a lack of motivation, depression, and disturbances in mood and cognition. Although cancer-related fatigue can occur independently of physical performance level [22], the present survey suggests that patients with low physical performance levels were more depressed, anxious, and socially insecure. In addition, pain or depression was more likely to occur in patients experiencing fatigue on a daily basis than in those experiencing it less frequently. Available evidence suggests that these symptoms are correlated with fatigue in cancer patients [4, 12, 21]. The cause-and-effect relationships among pain and psychological distress and the physical manifestations of cancer-related fatigue remain unclear, however, and require further investigation [13, 15, 18, 22, 25].
The ability to work is considered a concrete indicator of quality of life [26]. The reported impact of fatigue on the abilities of patients to continue working normally was substantial in the present survey. More than 75% of patients admitted changing their responsibilities because of fatigue. Furthermore, more than 20% of patients stopped working completely or went on disability. An interesting finding of our survey was the high occupational impact of the patients' cancer treatment on primary caregivers. Twelve percent of cancer patients reported that their primary caregiver was forced to take unpaid leave or stop working completely.
Our initial fatigue survey showed that fatigue was undertreated and seldom discussed among patients, caregivers, and oncologists [6]. Similarly, 40% of patients with fatigue in the present survey indicated that they were not offered any recommendations for reducing possible contributing factors or achieving symptomatic relief. The rate of discussion with health care professionals (92%) was encouraging; however, it is important to note that 45% of patients did not discuss fatigue more often because they believed nothing could be done to relieve it. As in our initial survey, bed rest/relaxation was the most common recommendation for relieving fatigue despite the potential physical and psychologic benefits of exercise in cancer patients [22, 27-30]. Although patients may benefit from correction of potential etiologies and comorbidities (e.g., pain, depression, anemia, and metabolic/nutritional abnormalities), these strategies were not pursued [2, 3, 16]. Further education for cancer patients, caregivers, and health care professionals on the availability of effective strategies and the development of individualized treatment plans targeted at alleviating fatigue is warranted. In addition, the importance of discussing fatigue with health care professionals should be emphasized to patients [2].
| CONCLUSION |
|---|
|
|
|---|
| APPENDIX |
|---|
|
|
|---|
The Fatigue Coalition
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
N.J.V. represents The Fatigue Coalition.
| References |
|---|
|
|
|---|
Related articles in The Oncologist:
This article has been cited by other articles:
![]() |
B. D. Thombs, M. Bassel, L. McGuire, M. T. Smith, M. Hudson, and J. A. Haythornthwaite A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples Rheumatology, October 1, 2008; 47(10): 1559 - 1563. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Dy, K. A. Lorenz, A. Naeim, H. Sanati, A. Walling, and S. M. Asch Evidence-Based Recommendations for Cancer Fatigue, Anorexia, Depression, and Dyspnea J. Clin. Oncol., August 10, 2008; 26(23): 3886 - 3895. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Bower Behavioral Symptoms in Patients With Breast Cancer and Survivors J. Clin. Oncol., February 10, 2008; 26(5): 768 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Radbruch, F. Strasser, F. Elsner, J. F. Goncalves, J. Loge, S. Kaasa, F. Nauck, P. Stone, and the Research Steering Committee of the European As Fatigue in palliative care patients -- an EAPC approach Palliative Medicine, January 1, 2008; 22(1): 13 - 32. [Abstract] [PDF] |
||||
![]() |
H. Sikand, A. Decter, T. Greco, S. H Watson, Y. J. Kang, S. H Mody, C. T. Piech, M. S. Duh, and A. Naeem Cost Analytic Model to Determine the Least Costly Inpatient Erythropoiesis Stimulating Therapy Regimen Ann. Pharmacother., January 1, 2008; 42(1): 16 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Muller and D. Baribeault Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2547 - 2556. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Courneya, R. J. Segal, J. R. Mackey, K. Gelmon, R. D. Reid, C. M. Friedenreich, A. B. Ladha, C. Proulx, J. K.H. Vallance, K. Lane, et al. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial J. Clin. Oncol., October 1, 2007; 25(28): 4396 - 4404. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Charu, C. P. Belani, A. N. Gill, M. Bhatt, D. Tomita, G. Rossi, and A. Ben-Jacob Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial Oncologist, June 1, 2007; 12(6): 727 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Boccia, T. Lillie, D. Tomita, and L. Balducci The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia Oncologist, May 1, 2007; 12(5): 584 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hofman, J. L. Ryan, C. D. Figueroa-Moseley, P. Jean-Pierre, and G. R. Morrow Cancer-Related Fatigue: The Scale of the Problem Oncologist, May 1, 2007; 12(suppl_1): 4 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Carroll, S. Kohli, K. M. Mustian, J. A. Roscoe, and G. R. Morrow Pharmacologic Treatment of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 43 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Mustian, G. R. Morrow, J. K. Carroll, C. D. Figueroa-Moseley, P. Jean-Pierre, and G. C. Williams Integrative Nonpharmacologic Behavioral Interventions for the Management of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 52 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A Echteld, L. van Zuylen, M. Bannink, E. Witkamp, and C. C. Van der Rijt Changes in and correlates of individual quality of life in advanced cancer patients admitted to an academic unit for palliative care Palliative Medicine, April 1, 2007; 21(3): 199 - 205. [Abstract] [PDF] |
||||
![]() |